Navidea Biopharmaceuticals, Inc. s in-depth stock price analysis indicates that the stock price has dropped -55.94% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -36.19% . Looking at the past 52 week period, the stock price is down -62.07% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Navidea Biopharmaceuticals, Inc. has a negative value of -32.5 compared to overall market performance. Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) has tumbled 33.89% during the past week and has dropped 45.44% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 34.42%. Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) has underperformed the index by 46.41% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.1094 points or 24.14% at $0.3437 with 6,284,119 shares getting traded. Post opening the session at $0.4599, the shares hit an intraday low of $0.29 and an intraday high of $0.4708 and the price was in this range throughout the day. The company has a market cap of $55 million and the number of outstanding shares has been calculated to be 161,190,990 shares. The 52-week high of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) is $1.51 and the 52-week low is $0.2602.
Navidea Biopharmaceuticals Inc Last issued its quarterly earnings results on Mar 15, 2016. The company reported $-0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $-0.03. The company had revenue of $4.00 million for the quarter, compared to analysts expectations of $3.70 million. The companys revenue was up 81.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.
Company has reported several Insider transactions to the SEC, on Dec 3, 2015, Brent L Larson (EVP, CFO, Treas & Secy) sold 12,500 shares at 1.50 per share price.On Jun 1, 2015, Gordon A Troup (director) purchased 10,000 shares at 1.31 per share price.On Jun 1, 2015, Brendan A Ford (director) purchased 20,000 shares at 1.31 per share price.
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Companys radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio.